To include your compound in the COVID-19 Resource Center, submit it here.

Galectin sinks after NASH candidate misses in Phase IIb

Galectin Therapeutics Inc. (NASDAQ:GALT) fell $0.76 (31%) to $1.72 on Tuesday after reporting that galactoarabino-rhamnogalacturonate (GR-MD-02) missed the primary endpoint of reducing hepatic venous pressure gradient

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE